10th Edition
R&D Controlling and Performance Management
Improve Decision-Making with Latest R&D Performance Techniques and Maximize your Business Impact
ENTER YOUR DETAILS FOR THE CONFERENCE AGENDA
What challenges and successes have you encountered in R&D portfolio valuation?
The alignment of assumptions between external deals and internal projects has been an area of focus. Having one set of guidelines for the whole company, whatever the use of the valuation is also an area of challenge, with recent sucess regarding the valuation of Intangible Assets.
What strategies do you use to eliminate delays and bottlenecks between research, development and commercial phases?
Key of success is the co-development of the different teams, by opposition to the “passing on the project”. So not working in sequence but in a collaborative parallel.
In your experience, how can performance measurement and robust governance improve project excellence?
Robust governance ensures proper prioritization of projects and proper allocation of resources, contributing to a solid pipeline of R&D Projects.
What is more crucial about performance measurement in R&D is how you track the value created within a year, when the value of projects could be in several years, especially in the pharmaceutical domain. It’s thus very key to set the right KPI for R&D performance, on top of R&D expenditures and project milestones tracking.
How do you balance the pursuit of long-term innovation with short-term performance goals when allocating resources?
A possible strategy is to set money aside for early research project, for Innovation when allocating resources, and start the prioritization for more advanced projects, like in the pharmaceutical domain, the clinical projects.
Ahead of the 10th Edition R&D Controlling and Performance Management conference we spoke with Camille Prado, R&D Finance Senior Director at GSK, Belgium. Camille is an experienced and enthusiastic Finance Director in pharma, biotech and other industries with background in finance partnering, BD, controlling, accounting, portfolio prioritisation and corporate governance leading change hand in hand with business.
11-13 March, 2024
Vienna, Austria
Camille will be presenting a case study during day one of the 10th Edition R&D Controlling and Performance Management conference!
Case Study: The Use of Project valuation in Pharma
- Where are project valuations performed in a corporation?
- For which purposes are those valuations used?
- Impact on external reporting: example of how intangible assets valuations are used
For registration pricing and multiple attendee discounts, please contact:
Ria Kiayia
All Rights Reserved. marcus evans ® 2024
Interested? Do you feel you will benefit?
An interview with Camille Prado, R&D Finance Senior Director at GSK, Belgium
Based on your experience what strategies or methods have proven effective in complex and faster-changing environments?
To face complexity and fast changing, key is more dynamic prioritization and more collaborative teams. Often people have a tendency to reduce teams to go faster, however it’s more appropriate to have a efficient collaboration.
